Sign in

You're signed outSign in or to get full access.

Jana

Research Analyst at TD Cowen

Jana Zinn is Managing Director and Head of Corporate Access & Advisory at TD Cowen, specializing in capital markets and corporate advisory services. She works closely with companies in the AI, technology, and capital markets sectors, providing strategic access and insights, though specific performance metrics or company coverage are not publicly reported. Jana has led corporate access and advisory initiatives since joining TD Cowen, and her previous experience includes significant work in related fields, though earlier employers and exact career dates are undisclosed. Her role as Managing Director implies advanced professional credentials and regulatory compliance, although specific securities licenses or FINRA registrations are not confirmed in public sources.

Jana's questions to AtriCure (ATRC) leadership

Question · Q4 2025

Jana asked about AtriCure's pain management expansion, specifically how long sales representatives typically stay in an account before moving to the next. She also inquired about the remaining runway for open ablation from a CABG perspective, including the percentage penetration and the impact of BoxX-NoAF.

Answer

Mike Carrel, President and CEO of AtriCure, explained that the duration reps stay in an account is not time-based but case-based, aiming for 10-15 cases and proper protocol establishment (including post-op care). This typically takes about three months. He noted that almost every rep has an account actively using the product, indicating good progress. Mr. Carrel stated that for AFib patients undergoing CABG, penetration is around 20%. However, when considering the broader opportunity including non-AFib patients (BoxX-NoAF trial), the penetration is 'much less than 10%,' indicating a significant market opportunity.

Ask follow-up questions

Fintool

Fintool can predict AtriCure logo ATRC's earnings beat/miss a week before the call

Jana's questions to Legend Biotech (LEGN) leadership

Question · Q3 2025

Jana, on behalf of Clara Dong, requested comments on Legend Biotech's strong international growth, identifying areas of strongest demand and higher growth potential after the TechLane facility comes online, and how TechLane's capacity will impact E.U. market share in 2026 and beyond.

Answer

Alan Bash, President of CARVYKTI, highlighted strong international uptake in Germany, Spain, and Belgium, noting that European markets value CARVYKTI's one-time infusion, durability, and PFS/OS benefits, supporting earlier use. He confirmed that TechLane is now commercially online and, combined with Ovalt, will meet the capacity demands for growing European launches.

Ask follow-up questions

Fintool

Fintool can predict Legend Biotech logo LEGN's earnings beat/miss a week before the call